Human tissue kallikreins 3 and 5 can act as plasminogen activator releasing active plasmin

Biochemical and Biophysical Research Communications

Volumn 433, Issue 3, 2013, Pages 333-337

  De Souza, Lucas R ^a   M Melo, Pollyana ^b   Paschoalin, Thaysa ^b   Carmona, Adriana K ^b   Kondo, Marcia ^b   Hirata, Izaura Y ^b   Blaber, Michael ^c   Tersariol, Ivarne ^d   Takatsuka, Joyce ^e   Juliano, Maria A ^b   Juliano, Luiz ^b   Gomes, Roseli A ^e   Puzer, Luciano ^a  

^a UNIVERSIDADE FEDERAL DO ABC   (Brazil)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^c FLORIDA STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^d UNIVERSIDADE DE MOGI DAS CRUZES   (Brazil)

^e FEDERAL UNIVERSITY OF TRIÂNGULO MINEIRO   (Brazil)

Author keywords

Kallikrein; Plasmin; Plasminogen; Protease

Indexed keywords

GLYCOSAMINOGLYCAN; KALLIKREIN; KALLIKREIN 3; KALLIKREIN 5; PLASMIN; PLASMINOGEN; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; FLUORESCENCE RESONANCE ENERGY TRANSFER; HYDROLYSIS; METASTASIS; NONHUMAN; PRIORITY JOURNAL; UPREGULATION;

AMINO ACID SEQUENCE; BACULOVIRIDAE; CHROMOGENIC COMPOUNDS; ENZYME ASSAYS; FIBRINOLYSIN; HUMANS; KALLIKREINS; KINETICS; MOLECULAR SEQUENCE DATA; PLASMINOGEN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEOLYSIS; RECOMBINANT PROTEINS; SOLUTIONS; TISSUE PLASMINOGEN ACTIVATOR;

EID: 84876319093     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2013.03.001     Document Type: Article

References (19)

1. Yousef G.M., Diamandis E.P. The new human tissue kallikrein gene family: structure, function, and association to disease. Endocr. Rev. 2001, 22:184-204.
2. Pampalakis G., Sorotipoulou G. Tissue kallikrein proteolytic cascade pathways in normal physiology and cancer. Biochim. Biophys. Acta 2007, 1776:22-31.
3. Borgono C.A., Diamandis E.P. The emerging roles of human tissue kallikreins in cancer. Nat. Rev. Cancer 2004, 4:876-890.
4. Luo L., Jiang W. Inhibition profiles of human tissue kallikreins by serine protease inhibitors. Biol. Chem. 2006, 387:813-816.
5. Michael I.P., Sotiropoulou G., Pampalakis G., Magklara A., Ghosh M., Wasney G., Diamandis E.P. Biochemical and enzymatic characterization of human kallikrein 5 (hK5), a novel serine protease potentially involved in cancer progression. J. Biol. Chem. 2005, 280:14628-14635.
6. Heidtmann H.H., Nettelbeck D.M., Mingels A., Jäger R., Welker H.G., Kontermann R.E. Generation of angiostatin-like fragments from plasminogen by prostate-specific antigen. Br. J. Cancer 1999, 81:1269-1273.
7. Petersen T.E., Martzen M.Q., Ichinose A., Davie E.W. Characterization of the gene for human plasminogen, a key proenzyme in the fibrinolytic system. J. Biol. Chem. 1990, 265:6104-6111.
8. Frenette G., Tremblay R.R., Lazure C., Dube J.Y. Prostatic kallikrein hk2, but not prostate-specific antigen (hk3), activates single-chain urokinase-type plasminogen activator. Int. J. Cancer 1997, 71:897-899.
9. Galaup A., Magnon C., Rouffiac V., Opolon P., Opolon D., Lassau N., Tursz T., Perricaudet M., Griscelli F. Full kringles of plasminogen (aa 1-566) mediate complete regression of human MDA-MB-231 breast tumor xenografted in nude mice. Gene Ther. 2005, 12:831-842.
10. Huang G., Hu Z., Li M., Cui Y., Li Y., Guo L., Jiang W., Lu S.H. ECRG2 inhibits cancer cell migration, invasion and metastasis through the downregulation of uPA/plasmin activity. Carcinogenesis 2007, 28:2274-2281.
11. Tan X., Egami H., Nozawa F., Abe M., Baba H. Analysis of the invasion-metastasis mechanism in pancreatic cancer: involvement of plasmin(ogen) cascade proteins in the invasion of pancreatic cancer cells. Int. J. Oncol. 2006, 28:369-374.
12. Kobayashi H., Shinohara H., Takeuchi K. Inhibition of the soluble and the tumor cell receptor-bound plasmin by urinary trypsin inhibitor and subsequent effects on tumor cell invasion and metastasis. Cancer Res. 1994, 54:844-849.
13. Teixeira T.S.P., Freitas R.F., Abrahão O., Devienne K.F., de Souza L.R., Blaber S.I., Blaber M., Kondo M.Y., Juliano M.A., Juliano L., Puzer L. Biological evaluation and docking studies of natural isocoumarins as inhibitors for human kallikrein 5 and 7. Bioorg. Med. Chem. Lett. 2011, 21:6112-6115.
14. Hirata I.Y., Cezari M.H.C., Nakaie C.R., Boshcov P., Ito A.S., Juliano M.A., Juliano L. Internally quenched fluorogenic protease substrates: solid-phase synthesis and fluorescent spectroscopy of peptides containing ortho-aminobenzoil/dinitrophenyl groups as donor-acceptor pairs. Lett. Pept. Sci. 1995, 1:299-308.
15. Andrade D., Assis D.M., Lima A.R., Oliveira J.R., Araujo M.S., Blaber S.I., Blaber M., Juliano M.A., Juliano L. Substrate specificity and inhibition of human kallikrein-related peptidase 3 (KLK3 or PSA) activated with sodium citrate and glycosaminoglycans. Arch. Biochem. Biophys. 2010, 498:74-82.
16. Andrade-Gordon P., Strickland S. Interaction of heparin with plasminogen activators and plasminogen: effects on the activation of plasminogen. Biochemistry 1986, 25:4033-4040.
17. Zhang L. Glycosaminoglycan (GAG) biosynthesis and GAG-binding proteins. Prog. Mol. Biol. Transl. Sci. 2010, 93:1-17.
18. Emami N., Diamandis E.P. Utility of kallikrein-related peptidases (KLKs) as cancer biomarkers. Clin. Chem. 2008, 54:1600-1607.
19. Avgeris M., Mavridis K., Scorilas A. Kallikrein-related peptidases in prostate, breast, and ovarian cancers: from pathobiology to clinical relevance. Biol. Chem. 2012, 393:301-317.